Advanced Pharmaceutical Technology recalled 22,843 cartons of TESTO-100 CIII testosterone pellets on October 3, 2025. The recall follows a risk of microbial contamination that could compromise product sterility. Consumers and healthcare providers should stop using the product immediately and seek guidance.
Lack of Assurance of Sterility: Potential microbial contamination of subcutaneous pellets.
Consumers and healthcare providers should stop using this product immediately. Contact Advanced Pharmaceutical Technology, Inc. or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recall involves TESTO-100 CIII testosterone pellets, 100 mg, sold in cartons of 10 sterile pellets. The affected lot number is P-22-3, with an expiration date of June 2027. The product was distributed in Georgia, New York, Texas, Puerto Rico, the United Kingdom, Malta, and Greece.
The recall stems from a lack of assurance of sterility due to potential microbial contamination of the subcutaneous pellets. Contaminated products may pose serious health risks to users.
There have been no reported injuries or illnesses associated with this recall as of the latest report date. Zero incidents have been documented.
Consumers should stop using the product immediately. Contact Advanced Pharmaceutical Technology or a healthcare provider for further instructions. A notification letter will be sent to affected parties.
For more information, consumers can visit https://www.accessdata.fda.gov/scripts/enforcement/enforce_rpt-Product-Tabs.cfm?recall_number=D-0258-2026 or contact Advanced Pharmaceutical Technology directly.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.